Literature DB >> 9109831

Parotid sparing study in head and neck cancer patients receiving bilateral radiation therapy: one-year results.

J A Ship1, A Eisbruch, E D'Hondt, R E Jones.   

Abstract

Many patients with head and neck cancers receive radiation therapy as part of their treatment which frequently causes considerable morbidity, including various degrees of permanent salivary gland dysfunction. Three-dimensional treatment planning [3-DTP] and conformational dose delivery constitute a new therapeutic modality that conforms the high-dose radiation volume to the shape of the tumor volume while minimizing the dose to tissue that is not at risk of containing cancer. The treatment volumes for head and neck tumors as well as parotid glands can be well-defined on cross-sectional CT imaging techniques. The purpose of this investigation is to determine if 3-DTP and conformational dose-delivery could minimize radiation dose and salivary gland dysfunction to contralateral parotid glands in patients with head and neck cancers. Eleven patients with head and neck cancers who required bilateral radiation therapy were treated with 3-DTP. Unstimulated and stimulated bilateral parotid saliva was collected prior to radiotherapy, weekly during treatment, and 1, 3, 6, and 12 months after the completion of radiotherapy. Treated parotid glands received an average dose of 5745 cGy, while spared glands received only 1986 cGy (p < 0.0001). Unstimulated and stimulated parotid flow rates decreased dramatically in treated glands after the initiation of radiotherapy, remained at extremely low rates without any improvements, and were significantly lower at 1 year after radiotherapy compared with baseline. Conversely, parotid flow rates in spared glands underwent mild changes during radiotherapy and were approximately 50% of baseline values. The results of this study suggest that with the use of 3-DTP, contralateral parotid gland function can be partially preserved for at least 1 year in patients with head and neck cancers requiring bilateral radiation.

Entities:  

Mesh:

Year:  1997        PMID: 9109831     DOI: 10.1177/00220345970760031401

Source DB:  PubMed          Journal:  J Dent Res        ISSN: 0022-0345            Impact factor:   6.116


  8 in total

1.  The impact of dose on parotid salivary recovery in head and neck cancer patients treated with radiation therapy.

Authors:  Yun Li; Jeremy M G Taylor; Randall K Ten Haken; Avraham Eisbruch
Journal:  Int J Radiat Oncol Biol Phys       Date:  2006-12-04       Impact factor: 7.038

2.  Acupuncture-Like Transcutaneous Electrical Nerve Stimulation Versus Pilocarpine in Treating Radiation-Induced Xerostomia: Results of RTOG 0537 Phase 3 Study.

Authors:  Raimond K W Wong; Snehal Deshmukh; Gwen Wyatt; Stephen Sagar; Anurag K Singh; Khalil Sultanem; Phuc F Nguyen-Tân; Sue S Yom; Joseph Cardinale; Min Yao; Ian Hodson; Chance L Matthiesen; John Suh; Harish Thakrar; Stephanie L Pugh; Lawrence Berk
Journal:  Int J Radiat Oncol Biol Phys       Date:  2015-04-01       Impact factor: 7.038

3.  Patient reported outcome and experience measures of oral disease in oral medicine.

Authors:  R Ní Ríordáin; P Wiriyakijja
Journal:  Br Dent J       Date:  2017-11-03       Impact factor: 1.626

4.  Cytokines in saliva increase in head and neck cancer patients after treatment.

Authors:  Nickole Russo; Emily Bellile; Carol Anne Murdoch-Kinch; Min Liu; Avi Eisbruch; Greg T Wolf; Nisha J D'Silva
Journal:  Oral Surg Oral Med Oral Pathol Oral Radiol       Date:  2016-06-09

5.  Phase 2 results from Radiation Therapy Oncology Group Study 0537: a phase 2/3 study comparing acupuncture-like transcutaneous electrical nerve stimulation versus pilocarpine in treating early radiation-induced xerostomia.

Authors:  Raimond K W Wong; Jennifer L James; Stephen Sagar; Gwen Wyatt; Phuc Felix Nguyen-Tân; Anurag K Singh; Barbara Lukaszczyk; Francis Cardinale; Alexander M Yeh; Lawrence Berk
Journal:  Cancer       Date:  2012-01-17       Impact factor: 6.860

6.  Parotid-sparing intensity modulated versus conventional radiotherapy in head and neck cancer (PARSPORT): a phase 3 multicentre randomised controlled trial.

Authors:  Christopher M Nutting; James P Morden; Kevin J Harrington; Teresa Guerrero Urbano; Shreerang A Bhide; Catharine Clark; Elizabeth A Miles; Aisha B Miah; Kate Newbold; MaryAnne Tanay; Fawzi Adab; Sarah J Jefferies; Christopher Scrase; Beng K Yap; Roger P A'Hern; Mark A Sydenham; Marie Emson; Emma Hall
Journal:  Lancet Oncol       Date:  2011-01-12       Impact factor: 41.316

7.  Analysis of factors influencing the development of xerostomia during intensity-modulated radiotherapy.

Authors:  Ken Randall; Jason Stevens; Juan Fernando Yepes; Marcus E Randall; Mahesh Kudrimoti; Jonathan Feddock; Jing Xi; Richard J Kryscio; Craig S Miller
Journal:  Oral Surg Oral Med Oral Pathol Oral Radiol       Date:  2013-03-22

8.  The effect of parotid gland-sparing intensity-modulated radiotherapy on salivary composition, flow rate and xerostomia measures.

Authors:  T M Richards; T Hurley; L Grove; K J Harrington; G H Carpenter; G B Proctor; C M Nutting
Journal:  Oral Dis       Date:  2017-06-05       Impact factor: 3.511

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.